Vedanta Biosciences, Inc. Overview
Pro stress-test →Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota. Founded in 2010, the company is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. Lead drugs include VE303 to treat C. difficile infection (phase II), VE202 for inflammatory bowel diseases (phase I), VE800 for cancer immunotherapy (phase I), VE416 for food allergy (phase I), and VE707 for multi-drug resistant organisms (MDRO).
Strategic Profile
Pro stress-test →The company stands 4th in terms of total funding among its competitors. Vedanta Biosciences has raised $366M. As of February 28, 2026, the company has 97 employees. The latest funding round was a Series E round on February 23, 2024, led by Colorcon, with participation from AXA Investment Managers, AMR Action Fund, Gates Foundation, K2 HealthVentures, PureTech Health, Skyviews Life Science and Pfizer.
Competitive Landscape
Pro stress-test →Top competitors include Spero Therapeutics, ADMA Biologics and BioNTech. Seres Therapeutics, also founded in 2010 and based in Cambridge, focuses on microbiome therapeutics with products designed to prevent recurrence of C. difficile infection and support patients undergoing stem cell transplantation. Evelo Biosciences is a clinical-stage biotech focused on developing oral biologics, offering monoclonal microbials intended to modulate clinically validated pathways.
Industry Context
Vedanta Biosciences, Inc. operates in Microbiome therapeutics.
Key facts
Founded: 2010 · Headquarters: Cambridge, Massachusetts, US · Employees: 97 (as of February 2026) · Revenue: Estimated $50M-$100M